Gland Pharma Limited

Symbol: GLAND.NS

NSE

1688.1

INR

Market price today

  • 42.3302

    P/E Ratio

  • -1.6054

    PEG Ratio

  • 278.05B

    MRK Cap

  • 0.00%

    DIV Yield

Gland Pharma Limited (GLAND-NS) Financial Statements

On the chart you can see the default numbers in dynamics for Gland Pharma Limited (GLAND.NS). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Gland Pharma Limited, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

03836232427.224465
13122.3
7207.5
6511.4
5330.8

balance-sheet.row.short-term-investments

01927329268.919546.8
11427.3
4843.4
2783
0

balance-sheet.row.net-receivables

08715.312514.712726.8
7767.3
5520.5
0
0

balance-sheet.row.inventory

01945311856.712751.7
7562.8
9118.8
5128.3
3787.2

balance-sheet.row.other-current-assets

02477.81722.31292.9
10.5
7248.3
5681.9
0

balance-sheet.row.total-current-assets

069008.158520.851236.4
28462.9
23574.6
17321.6
14081.5

balance-sheet.row.property-plant-equipment-net

0173611726913244.4
11969
10950.3
10464.7
10327.3

balance-sheet.row.goodwill

0000
0
0
0
0

balance-sheet.row.intangible-assets

0116.6125.30
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0116.6125.30
0
0
0
0

balance-sheet.row.long-term-investments

0-733.72000-19477.3
16.6
13.3
0
0

balance-sheet.row.tax-assets

0958.9-415.10
0
0
0
0

balance-sheet.row.other-non-current-assets

01064.4836.119957.3
411.9
697.4
1508.4
-10327.3

balance-sheet.row.total-non-current-assets

018767.319815.413724.4
12397.5
11660.9
11973
10327.3

balance-sheet.row.other-assets

0000
0
0
0
328.6

balance-sheet.row.total-assets

087775.478336.264960.8
40860.4
35235.5
29294.7
24737.5

balance-sheet.row.account-payables

05873.54628.54007.3
2490.9
4462
2918.1
1892.9

balance-sheet.row.short-term-debt

07.12.63
10.2
6.2
5.1
0

balance-sheet.row.tax-payables

09.8179.8286.9
107.2
110
129
0

balance-sheet.row.long-term-debt-total

037.444.847
49.9
60.1
66.3
59.2

Deferred Revenue Non Current

049.955.556.7
58
201.6
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

0924.7552.663.3
171.2
117.9
38.7
641

balance-sheet.row.total-non-current-liabilities

0896.8939.8803.1
807.8
1287.8
1399.2
59.2

balance-sheet.row.other-liabilities

0000
0
0
0
1246.3

balance-sheet.row.capital-lease-obligations

06.38.19.3
10.5
11.4
12.2
0

balance-sheet.row.total-liab

08188.167605928.4
4398
6615.5
5191.1
3839.3

balance-sheet.row.preferred-stock

015.600
0
0
0
0

balance-sheet.row.common-stock

0164.7164.3163.6
154.9
154.9
154.9
154.9

balance-sheet.row.retained-earnings

060153.952343.440226.8
30257.2
22527.5
18008.9
15579.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

0-15.6114.5240.9
160.3
47.6
0
0

balance-sheet.row.other-total-stockholders-equity

019268.618953.918401.1
5889.9
5889.9
5939.7
-15734.2

balance-sheet.row.total-stockholders-equity

079587.271576.259032.4
36462.3
28620
24103.6
15734.2

balance-sheet.row.total-liabilities-and-stockholders-equity

087775.478336.264960.8
40860.4
35235.5
29294.7
0

balance-sheet.row.minority-interest

0000
0
0
0
0

balance-sheet.row.total-equity

079587.271576.259032.4
36462.3
28620
24103.6
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-

Total Investments

018539.3200069.5
11427.3
4843.4
2783
0

balance-sheet.row.total-debt

044.547.450
60.1
66.3
71.4
0

balance-sheet.row.net-debt

0-19044.4-3110.8-4868.3
-1634.9
-2297.7
-3657
-5330.8

Cash Flow Statement

The financial landscape of Gland Pharma Limited has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

cash-flows.row.net-income

010545.816185.513348.1
9928.7
6862.8
5014.6
4137.3

cash-flows.row.depreciation-and-amortization

01467.41103987.8
945.9
821.2
783.7
741.5

cash-flows.row.deferred-income-tax

00-4143.8-3254
-2778.3
0
0
0

cash-flows.row.stock-based-compensation

0046.2155.3
164.8
0
0
0

cash-flows.row.change-in-working-capital

0-4179.4-3930.8-4357.6
-799.4
-3539.4
-1934.3
-867.3

cash-flows.row.account-receivables

01440-4195.7-602
-805.2
-459
0
-750.9

cash-flows.row.inventory

0-7596.3895-5188.9
1556
-3990.5
-1341.1
-116.4

cash-flows.row.account-payables

01209.8658.51428.2
-2146.7
1130.1
0
0

cash-flows.row.other-working-capital

0767.2-1288.65.1
596.5
-220.2
-593.2
0

cash-flows.row.other-non-cash-items

0-4194.1-1352.4-830.4
-452.4
-2292
-1842.9
753.2

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-2231.2-5221.2-2287.8
-1946.6
-1357.4
-851.8
-1161.9

cash-flows.row.acquisitions-net

0-12705.66117.24.3
238.9
5.5
0
0

cash-flows.row.purchases-of-investments

0-4699.8-16818.1-13575.9
-6387.5
-2187.4
-2982
0

cash-flows.row.sales-maturities-of-investments

017405.410700.9-4.3
-238.9
-5.5
0
0

cash-flows.row.other-investing-activites

014313.1-4805623.7
673.3
403.5
245.4
195.3

cash-flows.row.net-cash-used-for-investing-activites

012081.9-10026.2-15240
-7660.8
-3141.4
-3588.4
-966.5

cash-flows.row.debt-repayment

0-1.1-1.4-8.9
-5.3
-4.3
-4.6
0

cash-flows.row.common-stock-issued

0215385.512418.1
0
0
3976.8
0

cash-flows.row.common-stock-repurchased

0000
0
0
-3976.8
0

cash-flows.row.dividends-paid

0000
0
0
0
0

cash-flows.row.other-financing-activites

0-64.7-35.2-24.6
-63.4
-27
-33.1
-1164.2

cash-flows.row.net-cash-used-provided-by-financing-activities

0149.234912384.6
-68.7
-31.2
-37.7
-1164.2

cash-flows.row.effect-of-forex-changes-on-cash

03033.135.8
51.1
-44.3
2.6
-35.4

cash-flows.row.net-change-in-cash

015900.8-1736.43229.7
-669
-1364.4
-1602.4
2598.5

cash-flows.row.cash-at-end-of-period

0190893188.24924.6
1695
2364
3728.4
5330.8

cash-flows.row.cash-at-beginning-of-period

03188.24924.61695
2364
3728.4
5330.8
2732.3

cash-flows.row.operating-cash-flow

03639.77907.76049.3
7009.4
1852.5
2021.1
4764.6

cash-flows.row.capital-expenditure

0-2231.2-5221.2-2287.8
-1946.6
-1357.4
-851.8
-1161.9

cash-flows.row.free-cash-flow

01408.52686.53761.5
5062.7
495.1
1169.4
3602.7

Income Statement Row

Gland Pharma Limited's revenue saw a change of NaN% compared with the previous period. The gross profit of GLAND.NS is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

income-statement-row.row.total-revenue

03624643841.434236.4
25717.8
19931.5
15800.6
14791.8

income-statement-row.row.cost-of-revenue

016854.321092.214918.7
11020.2
8570.2
6607.5
5824.8

income-statement-row.row.gross-profit

019391.722749.319317.6
14697.6
11361.3
9193.1
8967

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

02404.61682.8
9.8
5.8
2.8
0

income-statement-row.row.operating-expenses

010611.58745.57280.4
6072.6
5222.7
4611.1
-3315.1

income-statement-row.row.cost-and-expenses

027465.729837.722199.2
17092.8
13792.9
11218.6
2509.6

income-statement-row.row.interest-income

01794.21386.5859.5
514.9
433.1
271.7
128.2

income-statement-row.row.interest-expense

074.53429.1
62.5
26.2
32.5
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

01701.42185.21313.7
1319.9
619
432.6
201.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

02404.61682.8
9.8
5.8
2.8
0

income-statement-row.row.total-operating-expenses

01701.42185.21313.7
1319.9
619
432.6
201.4

income-statement-row.row.interest-expense

074.53429.1
62.5
26.2
32.5
0

income-statement-row.row.depreciation-and-amortization

01467.41103987.8
945.9
821.2
783.7
741.5

income-statement-row.row.ebitda-caps

0---
-
-
-
-

income-statement-row.row.operating-income

08844.414000.312034.5
8608.8
6243.8
4582
5578.7

income-statement-row.row.income-before-tax

010545.816185.513348.1
9928.7
6862.8
5014.6
5780.1

income-statement-row.row.income-tax-expense

02735.44068.93378.5
2200.1
2344.2
1804.1
1642.8

income-statement-row.row.net-income

07810.412116.69969.6
7728.6
4518.6
3210.5
4137.3

Frequently Asked Question

What is Gland Pharma Limited (GLAND.NS) total assets?

Gland Pharma Limited (GLAND.NS) total assets is 87775350000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.605.

What is company free cash flow?

The free cash flow is 35.155.

What is enterprise net profit margin?

The net profit margin is 0.134.

What is firm total revenue?

The total revenue is 0.189.

What is Gland Pharma Limited (GLAND.NS) net profit (net income)?

The net profit (net income) is 7810430000.000.

What is firm total debt?

The total debt is 44530000.000.

What is operating expences number?

The operating expences are 10611470000.000.

What is company cash figure?

Enretprise cash is 0.000.